FAGR Fagron SA

Rob ten Hoedt non-executive director of Fagron

Rob ten Hoedt non-executive director of Fagron

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 20 December 2019

Rob ten Hoedt non-executive director of Fagron

The Board of Directors of Fagron has decided, following the advice of the nomination and remuneration committee, to co-opt Rob ten Hoedt as non-executive and independent director of Fagron.

Koen Hoffman, chairman of the Board of Directors: “We are pleased to welcome Rob ten Hoedt on the Board of Directors. With his broad and international management experience and extensive background in the medical technology industry, he will be a valuable addition to our Board.”

The appointment of Mr. Ten Hoedt is subject to approval by the next general meeting of shareholders of Fagron.

Rob ten Hoedt (1960)

Rob ten Hoedt is President for Europe, the Middle East and Africa (EMEA) and member of the Executive Committee of Medtronic (). Ten Hoedt has held numerous international sales, marketing and general management positions in the medical technology industry and has been with Medtronic since 1991. He is also chairman of the board of Medtech Europe, the European trade association for the medical technology industry. Ten Hoedt, who has Dutch nationality, obtained a bachelor’s degree in commercial economics at the HEAO school for higher education and a master’s degree in marketing from the Netherlands Institute of Marketing (NIMA).

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For further information

Constantijn van Rietschoten

Chief Communications Officer

Tel. 85

 

Please open the link below for the press release:



EN
20/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq
 PRESS RELEASE

Fagron publishes its Annual Report 2025

Fagron publishes its Annual Report 2025 Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its Annual Report 2025, further to its earlier announcement of Fagron's annual financial results for the financial year 2025 on February 12, 2026. The Annual Report is available on Fagron's in both Dutch (official version, including the ESEF-tagged version) and English. It comprises the annual financial report relating to the consolidated f...

 PRESS RELEASE

Fagron publiceert haar Jaarverslag 2025

Fagron publiceert haar Jaarverslag 2025 Gereglementeerde informatieNazareth (België)/Rotterdam (Nederland), 6 maart 2026 – 7:00 CET Fagron publiceert haar Jaarverslag 2025 Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, publiceert vandaag haar Jaarverslag 2025, volgend op de eerdere bekendmaking van Fagron's jaarlijkse financiële resultaten over het boekjaar 2025 op 12 februari 2026.  Het Jaarverslag is beschikbaar op de van Fagron in zowel het Nederlands (officiële versie, inclusief ESEF-getagde versie) als in het Engels. Het Jaarverslag omvat het financieel...

 PRESS RELEASE

Fagron completes acquisition of Vepakum

Fagron completes acquisition of Vepakum Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, announces the successful completion of its acquisition of Vepakum in Latin America. The transaction, announced in December 2025, was finalized following regulatory clearance from CADE in early February 2026. Vepakum operates two facilities in São Paulo, Brazil, and specializes in high-quality pharmaceutical packaging solutions. The ac...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch